A Phase 1/2 interventional study of Placebo oral capsule and Atomoxetine Oral Capsule [Strattera] in Obstructive Sleep Apnea, sponsored by Brigham and Women's Hospital. Recruiting at 1 site in United States. Open to participants aged 21 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-07-10.
Sponsored by Brigham and Women's Hospital · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 42 studies in Sleep Apnea, Obstructive by Brigham and Women's Hospital — 12 open to participants now, 12 under way, none of them phase 3. Sleep Apnea, Obstructive · Brigham and Women's Hospital.
Among the 42 studies in Sleep Apnea, Obstructive by Brigham and Women's Hospital, this one is the 26th largest by planned enrollment, is one of 3 that started in 2022, is one of 13 in phase 1/2, reaches primary completion later than 6 of the 11 other live ones, and was the 32nd registered.
2,246 studies on the registry are indexed under Sleep Apnea, Obstructive; 476 are open to participants now.
Browse Sleep Apnea, Obstructive studies →12 of the 42 studies in Sleep Apnea, Obstructive by Brigham and Women's Hospital are open now, in 1 country. Recruiting first, the newest first:
Brigham and Women's Hospital · Sites in United States
Ages 18+
Brigham and Women's Hospital · Sites in United States
Ages 18–79
Brigham and Women's Hospital · Sites in United States
Ages 21–70
Brigham and Women's Hospital · Sites in United States
Ages 21–70
Brigham and Women's Hospital · Sites in United States
Ages 5–18
By country, each count listing its studies:
Of the 317 Sleep Apnea, Obstructive studies recruiting now, 149 (47%) set no upper age limit and 124 (39%) stop at 75 or younger; 53 take children under 18; 66 take healthy volunteers.
This study: 21 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
42 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 15 · Phase 2 21
First in 2004; this study’s year is marked. 3 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 18 is below the median of 52 across 1,476 interventional studies indexed under Sleep Apnea, Obstructive.
Median enrollment 22 across the 42 interventional studies. Of the 28 that completed or were terminated, 18 (64%) have results posted.
This tab as a report to print or save as PDF → With an account.
Brigham and Women's Hospital is the lead sponsor of 1,270 studies on the registry; 230 are open to participants now.
Of its 117 completed or terminated interventional studies of FDA-regulated products, 65 (56%) have results posted.
3 of the studies in Sleep Apnea, Obstructive by Brigham and Women's Hospital that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05350215Brigham and Women's HospitalAtomoxetine and DAW2022 on OSA Severity | 2026-12-01 |
| NCT06854211Brigham and Women's HospitalImpacts of Opioids on Respiratory Drive During Sleep | 2027-01-01 |
| NCT06043440Brigham and Women's HospitalDown Syndrome Obstructive Sleep Apnea | 2027-11-30 |
Add all 3 to your calendar (.ics) → With an account.
Among the 42 studies in Sleep Apnea, Obstructive by Brigham and Women's Hospital, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Obstructive sleep apnea (OSA) is common and has major health implications but treatment options are limited. In previous research atomoxetine and oxybutynin showed promising effect at reducing OSA severity, however they reduced arousal threshold, one of the key traits responsible for OSA. Since oxybutynin was used mainly as a hypnotic, but it is burdened by several anti-cholinergic side effects, DAW2020, a hypnotic which prolonged the total sleep time in a previous trial in OSA patients, could be a better candidate to associate with atomoxetine.
Two overnight sleep studies will be performed: a drug night and a placebo night, with a month of washout between treatments. The patient will breath spontaneously (without CPAP) for both nights. On the study nights, subjects will present to the laboratory in the evening and be instrumented with a full polysomnography for monitoring sleep, physiological variables (endotypes), and respiratory events. A history and physical examination will be performed on each night prior to beginning the study, as will a urine pregnancy test in premenopausal women. The drugs will be administered as follows. There will be a 3-day run in of atomoxetine 40 mg followed by atomoxetine 80 mg starting on the fourth night until the night of the study. DAW2020 34 mg will be administered for 1-week to allow adequate plasma concentrations to be reached. For the sleep study, at least four hours of sleep (50% in the supine position) will be monitored to assess sleep and respiratory variables.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Placebo (2 pills) before sleep for a week
Drug: Placebo oral capsule
DAW2020 34 mg 4 h before sleep, single night administration for a week. Simultaneous administration of atomoxetine 40 mg for 3 days 30 min before sleep, 80 mg for the following 4 days, 30 min before sleep
Drug: Atomoxetine Oral Capsule [Strattera]
Placebo pills for a week, 1 pill 4 hr before sleep and 1 pill 30 min before sleep
Atomoxetine for a week: 40 mg for 3 days 30 min before sleep, 80 mg for 4 days 30 min before sleep Simultaneous administration of DAW2020 for a week, 34 mg 4 h before sleep
Also known as: DAW2020 Oral Capsule
Effect of atomoxetine and DAW2020 on OSA severity
OSA severity will be quantified by the number of respiratory events/h (AHI)
Time frame: 1 week
Effect of atomoxetine and DAW2020 on arousal index
Arousal index will be calculated as the number of arousal per hour
Time frame: 1 week
Effect of atomoxetine and DAW2020 on nadir oxygen desaturation
Nadir oxygen desaturation will be calculated as the lowest oxygen saturation value during sleep
Time frame: 1 week
Plan to share: No
Started Jun 2022 (actual). Primary completion is estimated for Dec 2026, 54 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Atomoxetine
Brigham and Women's Hospital →